Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Bought by Fmr LLC

Fmr LLC lifted its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 26.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 92,498 shares of the company’s stock after acquiring an additional 19,622 shares during the period. Fmr LLC owned 0.17% of Voyager Therapeutics worth $541,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in VYGR. Armistice Capital LLC lifted its holdings in Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after purchasing an additional 528,000 shares in the last quarter. Great Point Partners LLC purchased a new position in shares of Voyager Therapeutics during the second quarter valued at approximately $12,668,000. American Century Companies Inc. boosted its position in Voyager Therapeutics by 32.4% during the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after acquiring an additional 249,659 shares during the last quarter. Federated Hermes Inc. grew its stake in Voyager Therapeutics by 0.5% in the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock worth $4,384,000 after acquiring an additional 2,638 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Voyager Therapeutics by 17.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock valued at $2,329,000 after acquiring an additional 44,289 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Insider Activity at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.53% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Finally, Citigroup assumed coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $17.00.

Voyager Therapeutics Trading Down 7.4 %

Shares of VYGR stock opened at $5.79 on Thursday. The firm has a fifty day simple moving average of $6.56 and a 200-day simple moving average of $7.13. The company has a market capitalization of $316.28 million, a PE ratio of 8.16 and a beta of 0.90. Voyager Therapeutics, Inc. has a twelve month low of $5.19 and a twelve month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same period last year, the firm earned ($0.59) earnings per share. Equities research analysts predict that Voyager Therapeutics, Inc. will post -0.89 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.